AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Wilson Disease

Recent research efforts aimed at curing Wilson Disease.

Last updated

Wilson Disease

Overview

Wilson Disease is a rare inherited disorder caused by harmful changes in both copies of the ATP7B gene. Without working ATP7B protein, the liver cannot properly move excess copper into bile for removal from the body. Copper then accumulates first in the liver and can later injure the brain, eyes, kidneys, blood cells, and other organs. It is estimated to affect roughly 1 in 30,000 people, and symptoms may begin in childhood, adolescence, or adulthood; liver disease, movement problems, psychiatric symptoms, and acute liver failure are among the possible presentations. GeneReviews: Wilson Disease

With early, consistent treatment, many people can prevent severe illness or stabilize existing disease. Current care is not a genetic cure: it requires lifelong copper-lowering treatment with chelators such as D-penicillamine or trientine, or zinc to reduce intestinal copper absorption, plus monitoring and dietary precautions. Liver transplantation can restore normal hepatic copper handling but is reserved for acute liver failure, decompensated cirrhosis, or failure or intolerance of medical therapy. GeneReviews: Wilson Disease NIDDK: Treatment of Wilson Disease

Scope of Recent Research (2020–present)

Since 2020, Wilson Disease cure research has shifted from largely mouse-based gene replacement toward human testing of liver-directed gene therapy and, more recently, mutation-specific genome editing. The dominant question is whether restoring ATP7B activity in enough liver cells can normalize copper handling durably enough for patients to stop conventional therapy safely. As of August 8, 2026, the field has one active late-stage-designed AAV gene-therapy program, a newly authorized first-in-human prime-editing study, and several promising preclinical RNA and vector approaches; however, no investigational therapy has yet demonstrated a durable clinical cure in peer-reviewed human data. ClinicalTrials.gov: UX701 Cyprus2+ Prime Medicine: PM577a clinical-trial clearance

Major Breakthroughs and Emerging Therapies

The most clinically advanced strategy is in vivo gene addition: delivering a functional ATP7B sequence to liver cells using an adeno-associated virus, or AAV. Ultragenyx’s UX701 is designed as a single intravenous infusion intended to restore hepatic ATP7B activity. In an October 2024 company update from the first 15 treated participants, six had fully tapered off chelators and/or zinc while maintaining copper-control measures at the reporting cutoff, and a seventh had begun tapering. These results are encouraging but preliminary, sponsor-reported, and not yet equivalent to proof of a durable cure. Ultragenyx: Stage 1 UX701 update ClinicalTrials.gov: UX701 Cyprus2+

A major engineering challenge is that the normal ATP7B coding sequence is large for an AAV vector. Researchers have addressed this with shortened “miniATP7B” constructs and with dual-AAV systems that deliver two pieces of the gene and use protein trans-splicing to reassemble full-length ATP7B inside liver cells. In mouse models, split-intein dual-AAV treatment reconstituted full-length human ATP7B and rescued copper-mediated liver injury, while a 2025 AAV8 miniATP7B study in an Atp7b R780L knock-in mouse model improved ceruloplasmin, hepatic and urinary copper measures, and liver pathology after one dose. Padula et al.: Full-length ATP7B reconstitution in mice Zeng et al.: AAV8-ΔC4ATP7B in a Wilson Disease mouse model

Precise gene editing has progressed rapidly. Prime Medicine’s PM577a uses lipid nanoparticles—small fat-based particles that preferentially deliver RNA medicines to the liver—to deliver a prime editor intended to correct the common ATP7B H1069Q variant directly in hepatocytes. In preclinical work, the company reported up to 80% precise correction in a humanized mouse model and up to 51% editing in nonhuman-primate liver cells with a surrogate editor; these findings have not yet been independently peer-reviewed as a clinical treatment result. Prime Medicine: Preclinical Wilson Disease prime-editing data A follow-on editor for the R778L variant, more frequent in East Asian populations, is in preclinical development. Prime Medicine: PM577a clinical-trial clearance

A third approach is messenger RNA replacement. Rather than permanently adding or editing DNA, this method supplies temporary instructions for cells to make ATP7B protein. A 2025 preclinical study reported a hepatocyte-targeted lipid nanoparticle carrying full-length ATP7B messenger RNA, with improved liver targeting, reduced copper-related abnormalities, and no organ toxicity signal in the tested animal models. This could avoid AAV’s DNA cargo-size constraint and may allow repeat dosing, but it remains preclinical. Ma et al.: ATP7B mRNA lipid-nanoparticle delivery The U.S. Food and Drug Administration granted orphan-drug designation to an ATP7B mRNA-lipid nanoparticle program sponsored by INNORNA USA in March 2025; this designation supports development incentives but is not evidence of clinical efficacy or approval. FDA: ATP7B mRNA-LNP orphan designation

Clinical Trials and Experimental Approaches

Ultragenyx sponsors the Cyprus2+ study of UX701, listed as an active, not recruiting Phase 1/2 trial with an operationally seamless development plan that includes dose finding, a randomized active-controlled Phase 3 stage, and at least five years of follow-up after treatment. The study began in September 2021, has an estimated enrollment of 82 adults, and lists primary completion in March 2029. Participants receive a one-time intravenous dose alongside corticosteroid and immunomodulatory prophylaxis intended to manage immune responses to the AAV vector. No trial results are posted in the registry. ClinicalTrials.gov: UX701 Cyprus2+

Vivet Therapeutics’ VTX-801 GATEWAY study was a Phase 1/2 single-dose AAV program using a shortened ATP7B gene. The Wilson Disease Association reports that Vivet terminated the program in October 2024 after dosing four people at two dose levels; according to that account, the tested doses appeared safe but did not produce a sufficiently large effect to justify escalation without additional funding. This setback is important evidence that liver gene delivery alone does not guarantee adequate clinical restoration of copper transport. Wilson Disease Association: Gene Therapy update EMA: VTX-801 orphan designation

Prime Medicine received New Zealand regulatory clearance on June 18, 2026, to begin a global open-label Phase 1/2 study of PM577a in adults and adolescents with Wilson Disease. The company expects initial enrollment to begin with clinically stable adults receiving standard care and plans to measure safety, copper movement using copper-64 positron-emission tomography, ceruloplasmin, non-ceruloplasmin-bound copper, 24-hour urinary copper, and—in some cases—liver copper by biopsy. The company projected initial clinical data in 2027. Prime Medicine: PM577a clinical-trial clearance

Methodologies and Scientific Approaches

Researchers use several complementary disease models: Atp7b-knockout mice, mice carrying disease-relevant variants such as R780L—the mouse equivalent of the human R778L variant—humanized liver models, patient-derived induced pluripotent stem cells, and nonhuman primates for delivery and safety studies. These systems help test whether a therapy restores ATP7B protein, improves copper export into bile, lowers liver copper, normalizes ceruloplasmin, and prevents or reverses liver injury. Zeng et al.: AAV8-ΔC4ATP7B in a Wilson Disease mouse model Prime Medicine: Preclinical Wilson Disease prime-editing data

Clinical development is also improving its measurement tools. Standard blood and urine copper tests remain central, but emerging programs are evaluating liver biopsy measurements and copper-64 positron-emission tomography to directly assess whether corrected liver cells are moving copper appropriately. The PM577a protocol is notable for incorporating copper-64 imaging as a functional readout rather than relying only on indirect laboratory markers. Prime Medicine: PM577a clinical-trial clearance

Leading Institutions and Funding

Commercial translation is currently led by Ultragenyx, sponsor of the UX701 Cyprus2+ study, and Prime Medicine, developer of PM577a and related liver-targeted editing candidates. Vivet Therapeutics helped establish the first wave of clinical AAV testing with VTX-801, although that program was terminated. ClinicalTrials.gov: UX701 Cyprus2+ Wilson Disease Association: Gene Therapy update Prime Medicine: PM577a clinical-trial clearance

Academic and translational work includes teams developing AAV strategies, including investigators behind dual-vector protein-trans-splicing and R778L-model studies, as well as Fudan University and DSciLab collaborators developing ATP7B mRNA-lipid nanoparticles. Public support includes disease-relevant basic-science grants such as NIH R01 NS109307, reported for ATP7B structural research. Patient organizations, especially the Wilson Disease Association, support education, registries, trial awareness, and research engagement. Padula et al.: Full-length ATP7B reconstitution in mice Ma et al.: ATP7B mRNA lipid-nanoparticle delivery ATP7B structure study Wilson Disease Association: Gene Therapy update

Strengths, Limitations, and Challenges

Wilson Disease is a comparatively strong candidate for a genetic cure because its primary cause is known, the liver is the main therapeutic target, and restoring ATP7B in a sufficient fraction of hepatocytes may correct the central copper-export defect. The early UX701 treatment-tapering signal, successful copper correction in several mouse studies, and advance of PM577a toward first-in-human dosing collectively support the biological rationale. Ultragenyx: Stage 1 UX701 update Zeng et al.: AAV8-ΔC4ATP7B in a Wilson Disease mouse model Prime Medicine: PM577a clinical-trial clearance

The obstacles are substantial. AAV has limited cargo capacity for full-length ATP7B, may provoke immune responses requiring immunosuppression, and is difficult to redose; mini-gene and dual-vector solutions may introduce their own performance risks. The VTX-801 termination shows that acceptable short-term safety does not necessarily translate into enough therapeutic effect. Gene editing could provide a more physiologic repair, but PM577a initially addresses only H1069Q, so additional editors will be needed for people with other disease-causing variants, and long-term monitoring must establish editing precision, durability, liver safety, and benefit for existing neurologic disease. Padula et al.: Full-length ATP7B reconstitution in mice Wilson Disease Association: Gene Therapy update Prime Medicine: PM577a clinical-trial clearance

Outlook and Future Directions

A broadly available nonsurgical cure for Wilson Disease is not yet close enough to promise, but the field has entered a consequential clinical-testing period. The most important milestones are durable UX701 outcomes showing safe copper control without chelators or zinc, long-term evidence that liver-directed treatment prevents progressive hepatic and neurologic injury, initiation and first human data from PM577a, and expansion of editing approaches beyond H1069Q to cover more of the genetically diverse Wilson Disease population. Until those results are independently replicated and followed for years, lifelong standard therapy remains essential. ClinicalTrials.gov: UX701 Cyprus2+ Prime Medicine: PM577a clinical-trial clearance GeneReviews: Wilson Disease

References

Don't see your disease? Request a report